沙利度胺在晚期胃癌治疗中的临床研究

Treatment of advanced gastric cancer with thalidomide

目的观察沙利度胺治疗不化疗或不能耐受化疗的晚期胃癌患者的生活质量及生存期的影响,并与最佳支持治疗相比较。方法随机将71例晚期胃癌患者随机分为沙利度胺组(治疗组,38例)和最佳支持治疗组(对照组,33例),观察两组1个月和3个月后患者体重增加、症状改善、QOL评分、外周血VEGF蛋白、bFGF蛋白的浓度及两组的1年生存期。结果治疗组在体重增加、症状改善、QOL评分均优于对照组(P<0.05);外周血VEGF蛋白、bFGF蛋白的浓度下降在治疗3月后有统计学意义;治疗组生存期高于对照组,但P>0.05,无统计学意义。治疗组主要不良反应为便秘、嗜睡和疲乏,发生率分别为31.6%、18.4%和13.2%,与对照组相比,差异无统计学意义(P>0.05)。结论沙利度胺可以改善晚期胃癌患者的一般状况及抗肿瘤血管生成。

Objective To compare the quality of life （QOL） and survival rate of patients with advanced cancerin treatment with thalidomide and with the best supports. Methods Seventy-one cases were divided randomly into the treatment group （thalidomide, n=38） and the control group （the best support treatment, n=33）. The patients in the treatment group were given thalidomide 100 mg qn and up to 200 mg qn, and those in the control group were given the best support treatment. All patients received three months treatment. Results The weight increase, symptom score, the increation of QOL were in the treatment group was better than that in the control group （P0.05）. There was no significance different in overall survival rate. The major adverse reactions were constipation, somnolence and fatigue in the treatment group （31.6% , 18.4% , 13.2% respectively）and there was no significant difference between two groups （P0.05）. Conclusion Thalidomide can improve QOL of patients with advanced oncology, and inhibiting tumor angiogenesis.